. Thus, G6PC2 has been proposed to modulate the beta cell glycolytic pathway and glucose-stimulated insulin secretion by antagonising the activity of glucokinase, the major beta cell glucose sensor [6] . Despite 50% amino acid sequence identity with G6PC, G6PC2 shows little or no enzymatic activity on glucose 6-phosphate hydrolysis [4] . However, we have recently shown that a frequent single nucleotide polymorphism (SNP) within the third intron of G6PC2 is strongly associated with fasting plasma glucose levels and insulin release indices in several independent European populations [6] . Another study independently confirmed our findings and reported several SNPs that had strong effects on fasting plasma glucose levels in the same locus [7] . In a Chinese population, Hu and colleagues identified a novel G6PC2 SNP rs16856187 that confers risk for type 2 diabetes [8] . These genetic findings in humans are consistent with G6pc2 invalidation that results in a decrease of approximately 13% in fasting glucose concentrations in mice [9] .
Inactivated heterozygous mutations of GCK that reduce the glucose input into the glycolytic pathway are responsible for MODY type 2; when homozygous, the mutations are responsible for a few cases of permanent neonatal diabetes mellitus. However, gain-of-function mutations that increase glucose metabolism in the beta cell are associated with a persistent phenotype of HI sensitive to diazoxide [1] [2] [3] . In order to evaluate whether gain-or loss-of-function mutations in G6PC2 may be a cause of monogenic forms of beta cell dysfunction in humans, we screened 88 patients for mutations of G6PC2. These patients had genetically unexplained non-autoimmune early infancy diabetes (EID) ( Analysis of the genomic sequence of G6PC2 revealed 19 rare (minor allele frequency ≤0.05) and nine frequent (minor allele frequency >0.05) variants (Table 2 ). All variants were present in the heterozygous state. They included four exonic and five intronic variants; the other extragenic variants were located in the promoter region and in the 3′-UTR. All four coding variants were located in exon 5 of G6PC2 ( Table 2) . Three of them were non-synonymous and had been described previously, with an assigned rs number from the dbSNP build 129 database (p.Y207S-rs2232323, p.V219L-rs492594 and p.S342C-rs2232328). The synonymous variant Our results do not support the notion that G6PC2 disruption may be a common cause of monogenic forms of beta cell dysfunction in humans, at least in our patient cohorts. These findings differ markedly from large epidemiology studies that showed strong associations between common DNA variations at the G6PC2 locus and fasting glucose level [6, 7] , or even type 2 diabetes in the Chinese population [8] . Such divergent data between the aetiologies of monogenic beta cell disorders and polygenic type 2 diabetes have already been highlighted in previous studies, which did not show that causal mutations in several genes (such as TCF7L2, HHEX or SLC30A8) led to monogenic beta cell dysfunction [10] [11] [12] , although these gene loci were confirmed to confer risk strongly for type 2 diabetes. Nonetheless, the approach of screening genes known to be involved in polygenic type 2 diabetes for mutations in rare monogenic diabetes has been remarkably fruitful, as exemplified by the pharmacogenetic impact of KCNJ11 mutations [13, 14] .
Following our study based on three limited patient cohorts, albeit representative of rare monogenic forms of beta cell dysfunction, it would obviously be informative to test the association between all the novel variants and fasting glucose level or multifactorial forms of type 2 diabetes at the population level. Finally, further molecular studies are still required to clarify the function of G6PC2 in the pancreatic beta cell, particularly with regard to a role in the glucose phosphorylation pathway.
